Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03173976 · ClinicalTrials.gov registry record · Phase 1
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
A Phase 1 study of Chondrosarcoma, sponsored by Mohammed Milhem.
- Active
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03173976: Active Phase 1 study of Chondrosarcoma, sponsored by Mohammed Milhem.
NCT03173976 is a Phase 1 study of Chondrosarcoma that is active but no longer recruiting, run by Mohammed Milhem. The registered enrollment target is 17 participants, below the 127-participant average among 11 other Chondrosarcoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03173976, a Phase 1 study of Chondrosarcoma, is active but no longer recruiting, sponsored by Mohammed Milhem.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this single arm open label phase 1b clinical study is to see what effect zoledronic acid has on tumors in patients with resectable any grade chondrosarcoma prior to surgery.
Primary Outcome
Toxicity will be assessed using the NIH-NCI Common Terminology Criteria for Adverse Events, version 4.0 (CTCAEv4.)
Conditions Studied
Interventions
- DRUG Zoledronic Acid
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-07-18 |
| Est. Completion | 2028-05-01 |
| Phase | Phase 1 |
What the registry record for NCT03173976 still lists
NCT03173976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 127-participant average among 11 other Chondrosarcoma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Chondrosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Zoledronic Acid is the first listed.
NCT03173976 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT03173976 about?
NCT03173976 is a clinical study titled "Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial". The purpose of this single arm open label phase 1b clinical study is to see what effect zoledronic acid has on tumors in patients with resectable any grade chondrosarcoma prior to surgery.
What is the current status of trial NCT03173976?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2017-07-18. Estimated completion is 2028-05-01.
What conditions does trial NCT03173976 study?
This clinical trial studies the following conditions: Chondrosarcoma.
What interventions are being tested in trial NCT03173976?
The interventions under investigation include: Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT03173976?
This trial is sponsored by Mohammed Milhem, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03173976 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chondrosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03173976's enrollment target sits among peer trials
17 10th of 11 higher than 2 of 11 other Chondrosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chondrosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
ACTIVE NOT RECRUITING · Phase 1
-
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
RECRUITING
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
RECRUITING
-
Long-Term Longitudinal QoL in Patients Undergoing EEA
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI